RECURRENT GLIOBLASTOMA

This early-stage study tests a new RNA-based vaccine for adults whose glioblastoma (a fast-growing brain cancer) has come back. The main goals are to see if the vaccine can be made safely and to find the best dose. About 24 participants will receive the vaccine to check for side …

This early-phase study tests a combination of two treatments for glioblastoma that has returned or not responded to standard therapy. The approach uses specially engineered immune cells (CAR T cells) designed to attack the tumor, along with drugs that boost the immune system's ab…

This early-phase trial tests a new type of immune cell therapy (CAR T cells) designed to target and kill glioblastoma, an aggressive brain cancer that has returned or worsened. The therapy uses a special targeting domain (chlorotoxin) to seek out cancer cells. The study involves …

This study tests a combination of a drug called niraparib and a device that delivers low-intensity electric fields (Tumor-Treating Fields) in 30 adults whose glioblastoma brain tumor has come back after radiation. The goal is to see if this treatment can shrink or stabilize the t…

This early-phase trial tests whether adding the drug mycophenolate mofetil (MMF) to radiation therapy is safe for people with glioblastoma, an aggressive brain cancer. About 68 participants with newly diagnosed or recurrent glioblastoma will receive MMF alongside radiation. The m…

This early-stage study tests a new drug (BGB-290) combined with chemotherapy (temozolomide) in adolescents and young adults with IDH-mutant gliomas, a type of brain tumor. The goal is to find the safest dose and check for side effects. About 78 participants with newly diagnosed o…

This study tests a drug called ACT001 in adults whose glioblastoma (a severe brain cancer) has come back after standard treatment. Only patients with a specific genetic marker (STAT3-high) are included. The goal is to see if the drug can shrink the tumor or keep it stable for at …

This study tests whether combining two immune-boosting drugs (tocilizumab and atezolizumab) with precise radiation can shrink or stabilize recurrent glioblastoma, an aggressive brain cancer. About 59 adults whose tumor returned after initial treatment will receive the combination…

This study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…

This early-phase trial tests a new approach for people with high-grade gliomas that have returned after prior treatment. Genetically modified neural stem cells are placed directly into the brain tumor to make it more sensitive to the chemotherapy drug irinotecan. The main goal is…

This study tests whether combining two immunotherapy drugs (relatlimab and nivolumab) can help people with glioblastoma that has returned after initial treatment. The drugs work by helping the body's immune system attack the tumor. The trial compares this combination to standard …

This study was designed to test a treatment using a patient's own immune cells (T cells) to fight recurrent glioblastoma, an aggressive brain cancer. The cells were to be activated in a lab to target cancer stem cells. However, the trial was withdrawn before any participants were…

This early-phase study tests a new immunotherapy for people with malignant glioma that has returned or not responded to standard treatment. Researchers take a patient's own T-cells (a type of immune cell), add a gene that helps them recognize and attack glioma cells, and infuse t…

This early-phase trial tests the safety and best dose of mycophenolate mofetil, a drug usually used to prevent organ rejection, when added to standard chemotherapy and radiation for glioblastoma. About 60 adults with newly diagnosed or recurrent glioblastoma will take part. The g…

This trial tests a device implanted in the skull that uses ultrasound to temporarily open the blood-brain barrier, allowing chemotherapy drugs to reach brain tumors more effectively. About 57 adults with recurrent glioblastoma will receive this treatment after surgery to remove t…

This study looks at whether a special type of MRI (DSC-MRI) can measure blood flow changes in brain tumors to quickly tell if a drug called bevacizumab is working. About 146 adults with recurrent glioblastoma will get the MRI before and after starting treatment. The goal is to se…

This early study looks at how two oral drugs, defactinib and VS-6766, build up in glioblastoma tumors and the surrounding brain tissue. Fourteen adults with new or returning glioblastoma who need surgery will take a single dose of one drug before their operation. The main goals a…